» Articles » PMID: 36136557

Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches

Overview
Journal Toxins (Basel)
Publisher MDPI
Specialty Toxicology
Date 2022 Sep 22
PMID 36136557
Authors
Affiliations
Soon will be listed here.
Abstract

Headaches are a very common condition that most people will experience many times during their lives. This article presents the primary headaches, which are a large group of diseases where the headache is not a symptom of another known disease. Tension-type headache affects approximately 80% of the general population, and the prevalence of migraine is estimated at 10-12%. Clinical data and experience to date have demonstrated that botulinum toxin may be an effective prophylactic treatment for chronic headache types. It has been used in neurology for the treatment of dystonia and blepharospasm. Now it has been approved to treat chronic migraine and has been shown to confer significant benefit in refractory cases. Based on clinical experience botulinum toxin has also been tried in other headache disorders. While it is intuitively attractive to think that due to its effect on pain by sensory modulation, there may also be efficacy in its use in chronic tension-type headache and cluster headache, so far, there is little evidence to support this. Botulinum toxin is effective in pain control through its interaction with the SNARE complex, which inhibits the release of neurotransmitters, such as glutamate, substance P and calcitonin gene-related peptide. OnabotulinumtoxinA is effective not only in headache frequency and pain intensity but in other parameters, including quality of life.

Citing Articles

Intradermally injected abobotulinumtoxinA administered preemptively before surgery alleviates post-surgical pain and normalizes behavior in a translational animal model.

Kalinichev M, Cornet S, Castel D, Meilin S, Horne R, Pons L Sci Rep. 2025; 15(1):6381.

PMID: 39984566 PMC: 11845676. DOI: 10.1038/s41598-025-90886-4.


Non-Migraine Head Pain and Botulinum Toxin.

Farham F, Onan D, Martelletti P Toxins (Basel). 2024; 16(10).

PMID: 39453207 PMC: 11511419. DOI: 10.3390/toxins16100431.


Treatment Patterns and Persistence Among Patients Newly Diagnosed With Migraine in South Korea: A Retrospective Analysis of Health Claims Data.

Kim K, Ko H, Bea S, Lee H, Shin J, Chu M J Clin Neurol. 2024; 20(5):529-536.

PMID: 39227336 PMC: 11372211. DOI: 10.3988/jcn.2023.0485.


The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine: understanding from diverse patient profiles in a single session.

Ilgaz Aydinlar E, Erdogan Soyukibar T, Yalinay Dikmen P Front Neurol. 2024; 15:1417303.

PMID: 38962481 PMC: 11219632. DOI: 10.3389/fneur.2024.1417303.


Evaluation of the Effect of Botulinum Toxin A on the Lymphatic Endothelial Cells.

Vasella M, Wolf S, Grunherz L, Kim B, Lindenblatt N, Giovanoli P Aesthetic Plast Surg. 2024; 48(21):4513-4522.

PMID: 38839615 PMC: 11588844. DOI: 10.1007/s00266-024-04061-7.


References
1.
Vo A, Satori R, Jabbari B, Green J, Killgore W, Labutta R . Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial. Aviat Space Environ Med. 2007; 78(5 Suppl):B113-8. View

2.
Lipton R, Cady R, Stewart W, Wilks K, Hall C . Diagnostic lessons from the spectrum study. Neurology. 2002; 58(9 Suppl 6):S27-31. DOI: 10.1212/wnl.58.9_suppl_6.s27. View

3.
Bratbak D, Nordgard S, Stovner L, Linde M, Folvik M, Bugten V . Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache. Cephalalgia. 2015; 36(6):503-9. PMC: 4853809. DOI: 10.1177/0333102415597891. View

4.
Dodick D, Mauskop A, Elkind A, DeGryse R, Brin M, Silberstein S . Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache. 2005; 45(4):315-24. DOI: 10.1111/j.1526-4610.2005.05068.x. View

5.
Roland S, Pripp A, Msomphora M, Kvarstein G . The efficacy of botulinum toxin A treatment for tension-type or cervicogenic headache: a systematic review and meta-analysis of randomized, placebo-controlled trials. Scand J Pain. 2021; 21(4):635-652. DOI: 10.1515/sjpain-2021-0038. View